Wang Shengjie, Liu Xinli, Chen Ying, Zhan Xiaozhen, Wu Tujin, Chen Bing, Sun Guangwen, Yan Songling, Xu Lin
Department of Thyroid and Breast Surgery, Fujian Medical University Xiamen Humanity Hospital.
Department of Medical Oncology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University.
Medicine (Baltimore). 2020 Mar;99(13):e19604. doi: 10.1097/MD.0000000000019604.
Many studies have been done to reported the value of SRY-related HMG-box Gene 2 (SOX2) in prognosis of solid tumors. But results were not particularly consistent among these studies because of the limitations of the small sample data.
We searched relevant studies published before November 2018 by PubMed, Web of Science and EMBASE. In this meta-analysis, hazard ratio (HR) values for overall survival (OS) were cumulatively pooled and quantitatively analyzed.
A meta-analysis based on 12 studies with 3318 patients was conducted to assess the potential correlation between SOX2 overexpression and OS in human solid tumors. A total of 12 studies (n = 3318) were assessed in the meta-analysis. It suggested that the high expression of SOX2 obviously indicates poor survival and prognosis in both univariate and multivariate analysis. In the univariate analysis, the combined HR for OS was 1.66 (95% confidence interval [CI]: 1.46-1.89, P < .001). The pooled HR of multivariate analysis for OS was 1.51 (95% confidence interval [CI]: 1.32-1.71, P < .001).
This meta-analysis indicated that the high expression level of SOX2 is significantly associated with a decline in survival of human with solid tumors. On the basis of the expression level in solid tumors, SOX2 is expected to be a meaningful prognostic biomarker and effective therapeutic target.
许多研究已报道了SRY相关高迁移率族盒基因2（SOX2）在实体瘤预后中的价值。但由于小样本数据的局限性，这些研究的结果并不特别一致。
我们通过PubMed、科学网和EMBASE检索了2018年11月之前发表的相关研究。在这项荟萃分析中，对总生存期（OS）的风险比（HR）值进行了累积合并和定量分析。
基于12项研究共3318例患者进行了一项荟萃分析，以评估SOX2过表达与人类实体瘤OS之间的潜在相关性。荟萃分析共评估了12项研究（n = 3318）。结果表明，在单变量和多变量分析中，SOX2的高表达均明显提示生存和预后不良。在单变量分析中，OS的合并HR为1.66（95%置信区间[CI]：1.46 - 1.89，P <.001）。OS多变量分析的合并HR为1.51（95%置信区间[CI]：1.32 - 1.71，P <.001）。
这项荟萃分析表明，SOX2的高表达水平与实体瘤患者生存率下降显著相关。基于实体瘤中的表达水平，SOX2有望成为一个有意义的预后生物标志物和有效的治疗靶点。
